Do you have a cancer that is advanced or metastatic? Has your cancer progressed on other standard of care therapies? If you answered yes, then this research study may be for you. Study drug will be provided

Do you identify as Black or African-American? Have you been diagnosed with colon cancer, rectal cancer, or colorectal cancer? If so, you may be able to take part in a study to see if an exercise program can help with cancer side effects and overall quality of life. Compensation provided,

Do you have relapsed peripheral T-cell lymphoma (PTCL)? Has your cancer not gotten better with other treatments, or were those treatments stopped because of bad side effects? If so, you might be able to join a study to see if a new drug called Soquelitinib (also known as CPI-818) can treat PTCL better.

Are you an adult who has just found out you have IDH-Wildtype Glioblastoma? If so, you could join a study to see if a new experimental pill called ropidoxuridine can help make treatment for this type of brain cancer better when used with radiation.

Have you been diagnosed with High-risk Biochemical Recurrence (BCR) of Nonmetastatic Castration-sensitive Prostate Cancer (nmCSPC)? If so, you may be able to take part in a research study evaluating the safety and tolerability of the study drug in adults with High-risk Biochemical Recurrence (BCR) of Nonmetastatic Castratio-sensitive Prostate Cancer (nmCSPC).

Do you have early-stage endometrial cancer? If so, you may be able to take part in a research study looking to find out if there are types of early-stage endometrial cancer that require less treatment than the usual approac

Do you have advanced melanoma that has progressed on treatment? Do you have a tumor longer than 1cm in length? If so, you might be able to take part in a study that compares a study treatment (Vusolimogene Oderparepvec and Nivolumab) with your physician's choice of standard of care treatment. Compensation provided.

Have you been diagnosed with hormone receptor (HR+) and human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic breast cancer? If so, you may be eligible for a clinical trial investigating the combination of endocrine therapy with alisertib.

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Are you a patient with advanced basal-like pancreatic adenocarcinoma? If so this could the a Trial for you to as this is a Phase I/II trial is to evaluate the safety, efficacy and tolerability of low-dose EGFR inhibitors in combination with bi-weekly gemcitabine/nab-paclitaxel (GnP) in subjects with basal tumors